ATE331503T1 - Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe - Google Patents

Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe

Info

Publication number
ATE331503T1
ATE331503T1 AT96930337T AT96930337T ATE331503T1 AT E331503 T1 ATE331503 T1 AT E331503T1 AT 96930337 T AT96930337 T AT 96930337T AT 96930337 T AT96930337 T AT 96930337T AT E331503 T1 ATE331503 T1 AT E331503T1
Authority
AT
Austria
Prior art keywords
tnf
alpha
necrosis factor
tumor necrosis
inhibiting drugs
Prior art date
Application number
AT96930337T
Other languages
German (de)
English (en)
Inventor
Esther Shohami
Ruth Gallily
Raphael Mechoulam
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE331503T1 publication Critical patent/ATE331503T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96930337T 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe ATE331503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE331503T1 true ATE331503T1 (de) 2006-07-15

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930337T ATE331503T1 (de) 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe

Country Status (9)

Country Link
US (3) US5932610A (enExample)
EP (1) EP0876143B1 (enExample)
JP (1) JP2000500737A (enExample)
AT (1) ATE331503T1 (enExample)
AU (1) AU708886B2 (enExample)
CA (1) CA2231764A1 (enExample)
DE (1) DE69636308T2 (enExample)
IL (1) IL115245A (enExample)
WO (1) WO1997011668A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
HUP0203437A3 (en) 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
AU5969101A (en) 2000-05-12 2001-11-26 Genzyme Corp Modulators of tnf-alpha signaling
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
WO2002026728A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
US7057076B2 (en) * 2001-07-13 2006-06-06 University Of Connecticut Bicyclic and tricyclic cannabinoids
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
JP4928079B2 (ja) * 2002-11-21 2012-05-09 ジェンザイム・コーポレーション 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
JP2006509038A (ja) * 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
NZ594077A (en) * 2005-09-29 2013-02-22 Albany Molecular Res Inc Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
US6545041B2 (en) 2003-04-08
IL115245A (en) 2002-12-01
AU708886B2 (en) 1999-08-12
US20020049245A1 (en) 2002-04-25
DE69636308T2 (de) 2007-05-31
WO1997011668A2 (en) 1997-04-03
JP2000500737A (ja) 2000-01-25
CA2231764A1 (en) 1997-04-03
EP0876143A2 (en) 1998-11-11
IL115245A0 (en) 1995-12-31
DE69636308D1 (de) 2006-08-10
US5932610A (en) 1999-08-03
EP0876143B1 (en) 2006-06-28
WO1997011668A3 (en) 1997-05-15
EP0876143A4 (en) 2001-06-27
AU6942096A (en) 1997-04-17
US6331560B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
ATE331503T1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
EP1299374A4 (en) NEW NON PSYCHOTROPICAL CANNABINOIDS
SG49625A1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
HU9301550D0 (en) New hydroxamine acid and n-hydroxy-carbamide derivatives and their applications
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
EP3081214A3 (en) Inhibitors of cellular necrosis
IL105219A0 (en) Cyclohexane-ylidene compounds and pharmaceutical compositions containing them
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
MY132705A (en) Novel compounds with analgesic effect
RU95108330A (ru) Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток. увеличения содержания гамма -интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
HRP20060276A2 (en) 6-0-supstituted ketolides having antibacterial activity
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
RU2004135078A (ru) Травяная молекула как потенциальное противолейкозное лекарственное средство
WO1993009766A1 (en) Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
WO2005004915A3 (en) Compositions comprising meloxicam
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
AU2420001A (en) Methods and compositions for the treatment of pain
BG103512A (en) Substituted pyramidine compounds and their application
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
CA2392902A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
EP1785417A3 (en) Novel non-psychotropic cannabinoids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties